Tuberculosis amidst COVID-19 pandemic in India: unspoken challenges and the way forward

被引:0
作者
Mainak Bardhan
Mohammad Mehedi Hasan
Ishita Ray
Anusua Sarkar
Priyanka Chahal
Sudhan Rackimuthu
Mohammad Yasir Essar
机构
[1] ICMR-National Institute of Cholera and Enteric Diseases,Division of Bacteriology
[2] Mawlana Bhashani Science and Technology University,Department of Biochemistry and Molecular Biology, Faculty of Life Science
[3] Mahatma Gandhi Memorial Medical College,Department of Biotechnology
[4] Heritage Institute of Technology,undefined
[5] S. Tentishev Asian Medical Institute,undefined
[6] Father Muller Medical College,undefined
[7] Kabul University of Medical Sciences,undefined
来源
Tropical Medicine and Health | / 49卷
关键词
Tuberculosis; COVID-19; India; Public health;
D O I
暂无
中图分类号
学科分类号
摘要
India is home to the most significant number of tuberculosis (TB) cases around the globe. The COVID-19 crisis has deeply perturbed most of the essential TB services in India. Regulating TB is difficult in a densely populated country like India due to latent TB infection in millions of Indians, which can reactivate at any point in the future. Due to the ongoing pandemic, healthcare workers have been diverted to activities implemented for effective COVID-19 management, leaving a meager workforce to help deal with TB management. Integrating TB and COVID-19 to augment India’s health outreach is the need of the hour to diminish the effect of the COVID-19 crisis on TB. Increasing overall testing capacity, active screening, implementation of strategies for easy identification of TB hotspots, and ensuring uninterrupted drug supply for treatment through heedful planning of local and regional distribution and transportation will especially help cater to the vulnerable population who are at a high risk of suffering from adverse outcomes of TB. Lessons learnt in the battle against COVID-19 can most definitely help in providing insights to fulfill the goal of eliminating TB from India.
引用
收藏
相关论文
共 106 条
[1]  
Khan FMA(2021)Resurgence of tuberculosis amid COVID-19 in Peru: associated risk factors and recommendations Int J Health Plann Manage 18 1644-1651
[2]  
Kazmi Z(2021)Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor Cell Mol Immunol 157 43-51
[3]  
Hasan MM(2021)Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis JAMA Dermatol 3 143-150
[4]  
Costa ACdS(2011)Tuberculosis: current situation, challenges and overview of its control programs in India J Glob Infect Dis 6 a018192-189
[5]  
Ahmad S(2016)Transmission and institutional infection control of tuberculosis Cold Spring Harb Perspect Med 42 185-133
[6]  
Essar MY(2020)Patterns and predictors of co-morbidities in tuberculosis: a cross-sectional study in the Philippines Sci Rep 43 1-undefined
[7]  
Robert M(2016)Tuberculosis Nat Rev Dis Prim 252 117594-undefined
[8]  
Miossec P(2020)India’s syndemic of tuberculosis and COVID-19 BMJ Glob Health 69 102740-undefined
[9]  
Elewski BE(2021)COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India Trop Med Int Health 14 1439-undefined
[10]  
Baddley JW(2021)Rampant increase in cases of mucormycosis in India and Pakistan: a serious cause for concern during the ongoing COVID-19 pandemic Am J Trop Med Hyg 68 128-undefined